Issue Archive
Table of Contents
Ham-Wasserman Lecture
Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative
Aggressive Non-Hodgkin Lymphomas: It’s Getting Personal
Aging and Hematologic Disorders: Exploring the Evidence
Balancing the Scales: Management of Patients at Risk of Bleeding and Clotting in the Acute Care Setting
Bone Marrow Failure and Clonal Evolution
Challenges in Myeloma Therapy
Coagulation Conundrum Roundtable: Case-Based Discussion on the Implications of Exogenous Estrogens in Hemostasis and Thrombosis
Combined Basic Science and Education Session on Cancer-Associated Thrombosis
DOACs in the Real World
Expanding Horizons for Immunotherapy in Pediatric Leukemia
Hodgkin Lymphoma: Celebrating 200 Years since Thomas Hodgkin Entered Medicine
Immunotherapy in Myeloma
Indolent Lymphomas: The Marathon Has a New Course
Inflammation and Hematopoiesis: The Impact of Inflammation on the Bone Marrow Microenvironment
Iron: How to Manage When There Is Too Much or Too Little of It
Management of Sickle Cell Disease Complications Beyond Acute Chest
Myelodysplastic Syndromes: From Mild-Mannered to Lurking Leukemia
Myeloproliferative Neoplasms: Managing the Cup That Runneth Over
New Diagnostic and Treatment Strategies for Antiphospholipid Syndrome
Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia
Primary Immunodeficiencies: Finding the Needle in the Haystack
Response Comes of Age in Chronic Lymphocytic Leukemia
Sickle Cell Disease in Young and Old: A Time for Re-Evaluation
Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation
Therapy of Acute Myeloid Leukemia: Adapting to Change
Transfusion Medicine: Optimizing Patient Blood Management (PBM)
What's New in the Diagnosis and Management of von Willebrand Disease?
Why Patients Fail after Allogeneic Stem Cell Transplantation
Erratum
-
Cover Image
Cover Image
T cells and brain cancer cell. The image is a composite colored scanning electron micrograph of T cells and an apoptotic brain cancer cell. T cells are a component of the body’s immune system. Chimeric antigen receptor (CAR) T-cell therapy takes T cells from a cancer patient’s blood and modifies them to recognize a specific protein found on the patient’s tumor cells. When reintroduced into the patient, the T cells find and destroy the tumor cells. The newest form of CAR T-cell therapy, now in clinical trials, uses “memory” T cells, which remain in the body after attacking the cancer. The hope is that memory T cells may provide an active reservoir of cancer-killing cells capable of stopping further tumors. Magnification ×6000 at 10 cm wide. Source: Steve Gschmeissner/Science Photo Library.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents